Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yevgeniy Balagula

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
International Journal of Dermatology|January 20, 2011
Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitorsYevgeniy Balagula, Claus Garbe, Patricia L Myskowski, et al.
American Journal of Clinical Dermatology|April 30, 2013
Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinicAlyx C Rosen, Emily C Case, Stephen W Dusza, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|November 19, 2011
Dermoscopic features of basal cell carcinomas: differences in appearance under non-polarized and polarized lightTracey N Liebman, Natalia Jaimes-Lopez, Yevgeniy Balagula, et al.
Journal of Cutaneous Pathology|October 27, 2018
Cryptococcus-like changes in the setting of vasculitisAmber Fresco, Jenny Wang, Aimee Krausz, et al.
Journal of the American Academy of Dermatology|October 28, 2011
The significance of crystalline/chrysalis structures in the diagnosis of melanocytic and nonmelanocytic lesionsYevgeniy Balagula, Ralph P Braun, Harold S Rabinovitz, et al.
Pediatric Dermatology|July 6, 2021
Heterogeneous cutaneous findings associated with intrauterine HSV infection: A case series and literature reviewDeeti J Pithadia, Michelle L Kerns, William C Golden, et al.
Anti-Cancer Drugs|October 11, 2013
Life-threatening dermatologic adverse events in oncologyAlyx C Rosen, Yevgeniy Balagula, Dennis W Raisch, et al.
Cancer|March 23, 2012
Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitorsYevgeniy Balagula, Alyx Rosen, Belinda H Tan, et al.
JAAD Case Reports|August 19, 2021
Mitomycin extravasation injury: A case seriesKarolina Mieczkowska, Alana Deutsch, Bijal Amin, et al.
JAAD International|February 3, 2026
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: Efficacy and safety results through week 16 in a phase 3b/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP)Kristina Callis Duffin, Christopher E M Griffiths, Matthias Hoffmann, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
International Journal of Dermatology|January 20, 2011
Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitorsYevgeniy Balagula, Claus Garbe, Patricia L Myskowski, et al.
American Journal of Clinical Dermatology|April 30, 2013
Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinicAlyx C Rosen, Emily C Case, Stephen W Dusza, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|November 19, 2011
Dermoscopic features of basal cell carcinomas: differences in appearance under non-polarized and polarized lightTracey N Liebman, Natalia Jaimes-Lopez, Yevgeniy Balagula, et al.
Journal of Cutaneous Pathology|October 27, 2018
Cryptococcus-like changes in the setting of vasculitisAmber Fresco, Jenny Wang, Aimee Krausz, et al.
Journal of the American Academy of Dermatology|October 28, 2011
The significance of crystalline/chrysalis structures in the diagnosis of melanocytic and nonmelanocytic lesionsYevgeniy Balagula, Ralph P Braun, Harold S Rabinovitz, et al.
Pediatric Dermatology|July 6, 2021
Heterogeneous cutaneous findings associated with intrauterine HSV infection: A case series and literature reviewDeeti J Pithadia, Michelle L Kerns, William C Golden, et al.
Anti-Cancer Drugs|October 11, 2013
Life-threatening dermatologic adverse events in oncologyAlyx C Rosen, Yevgeniy Balagula, Dennis W Raisch, et al.
Cancer|March 23, 2012
Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitorsYevgeniy Balagula, Alyx Rosen, Belinda H Tan, et al.
JAAD Case Reports|August 19, 2021
Mitomycin extravasation injury: A case seriesKarolina Mieczkowska, Alana Deutsch, Bijal Amin, et al.
JAAD International|February 3, 2026
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: Efficacy and safety results through week 16 in a phase 3b/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP)Kristina Callis Duffin, Christopher E M Griffiths, Matthias Hoffmann, et al.
Pageof 6